Yazar "Kandemir, E. G." seçeneğine göre listele
Listeleniyor 1 - 12 / 12
Sayfa Başına Sonuç
Sıralama seçenekleri
Yayın A Case report: large granular cell leukemia/lymphoma.(Turkish Society of Hematology, 2002) Öztürk, A.; Orhan, B.; Kandemir, E. G.; Yaylacı, M.We presented a 64-year-old male patient with T-large granular cell leukemia/lymphoma with an agressive clinical course. Large granular lymphocytes were noted on peripheral blood smear. The phenotyping of the cells was typical T-cell lineage [CD2 (+), CD3 (+), CD5 (+)]. Clonal rearrangement of the T-cell receptor gene (TCR) was demonstrated by DNA hybridization technique. Large granular cell leukemia/lymphoma is a distinct entity with spesific clinicobiological aspects. The clinical spectrum is wide and immunophenotyping and genotyping studies need to make a diagnosis.Yayın Cerebrovascular accident after chemotherapy for testicular cancer(Oxford Academic, 2009) Karagöz, B.; Bilgi, O.; Akyol, İ.; Özgün, Alpaslan; Kandemir, E. G.Arterial thromboembolic events are not common after chemotherapy. We present a case of a cerebrovascular accident, which developed after chemotherapy in a patient with a germ cell tumor. A 34-year-old man with a testicular germ cell tumor who did not have any comorbid disease was admitted to hospital. After a radical inguinal orchiectomy, BEP (bleomycin, etoposide, and cisplatin) chemotherapy regimen was given. On the 10th day of the third cycle, aphasia and hemiplegia developed. Cerebrovascular accident was diagnosed. This event is a rare complication in a patient receiving BEP chemotherapy who did not have cardiovascular disease or thromboembolic risk factors.Yayın D8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients(Springer Link, 2010) Karagöz, B.; Bilgi, O.; Gümüş, M.; Erikçi, A. A.; Sayan, O.; Kandemir, E. G.; Öztürk, A.; Yaylacı, M.Aim To evaluate the CD8+CD28? and CD4+CD25+ regulatory T (Treg) cells in addition to other some lymphocyte subgroups in peripheral blood of advanced stage lung cancer patients. Methods The study group (n = 28) comprised chemotherapy and radiotherapy naïve patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The control group (n = 22) consisted of age- and sex-matched healthy volunteers. Flow cytometry was used to count T cells, natural killer (NK) cells and CD4+CD25 Treg cells, and for CD8+ T cell subgroup analysis. Flow cytometry was performed and annexin V binding was used for apoptotic cell evaluation. Results In patient group, the percentage of CD8+CD28? cells among lymphocytes was elevated, and there was also an increase in the CD28?/CD28+ cell ratio among CD8 lymphocyte population. The distribution of CD8 cells was different in lung cancer patients when compared with the control group. The absolute count of CD4+CD25bright cells and the percentages of these cells among total lymphocytes were higher in the patient group. The Annexin V(+) cell percentages among CD8+CD28? and CD8+CD28+ lymphocytes were higher in the patient group than in the control group. No differences were found between the NSCLC and SCLC patients with respect to the hematological parameters and the distribution of lymphocyte subgroups. In NSCLC patients, the percentage of CD8+CD28? cells among the lymphocyte population was higher in patients with stage IV than those with stage III. Conclusion These findings may reflect the possibility of tumor-induced immunosuppression and they should be complemented with further studies.Yayın Hemicentral retinal artey occlusion in a breast cancer patient using anastrazole.(Karger, 2009) Karagöz, B.; Ayata, A.; Bilgi, O.; Uzun, G.; Ünal, M.; Kandemir, E. G.; Özgün, A.Background: Anastrozole, an aromatase inhibitor, is commonly used in the adjuvant treatment of breast cancer. Anastrozole treatment is associated with a risk of thromboembolic events and retinal vascular side effects. Herein, we present a case of hemicentral retinal artery occlusion diagnosed in a breast cancer patient using anastrozole. Case Report: A 53-year-old woman with a hypertensive and diabetic background was admitted to our hospital with breast cancer. Anastrozole treatment was started after surgery, adjuvant chemotherapy, and radiotherapy. Sudden painless loss of vision in the patient’s right eye occurred within 13 months of Anastrozole treatment. A fluorescein angiogram revealed hemicentral retinal artery occlusion. Conclusion: To the best knowledge of the authors, this is the first report of hemicentral retinal artery occlusion in an anastrozole user.Yayın Hyperammonemic encephalopathy in a patient with primary hepatic neuroendocrine carcinoma.(Springer Link, 2009) Başekim, C.; Haholu, A.; Karagöz, B.; Bilgi, O.; Özgün, A.; Küçükardalı, Y.; Narin, Y.; Yazgan, Y.; Kandemir, E. G.A 53-year-old male patient was admitted to our hospital with abdominal pain in the right upper quadrant. There was no change in laboratory investigations other than a slight increase in serum levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and gamma glutamyl transferase (GGT). Computed tomography (CT) of the abdomen showed multiple hepatic nodular lesions in the liver. Tru-cut biopsy of the lesions was reported as well-differentiated neuroendocrine carcinoma. The patient received sandostatin treatment. After a few days, the patient was hospitalized in the intensive care unit with disturbance of consciousness and clinical features suggestive of encephalopathy. Serum ammonia level was found highly elevated. After the treatment with L-ornithine-L-aspartate, a remarkable improvement in the level of patient's sensorium occurred as well as a reduction in serum ammonia level within a few days. Transarterial chemoembolization (TACE) was performed one week later. The patient's condition began to worsen along with increase in serum ammonia level and he died because of hyperammonemic encephalopathy. There are case reports of hyperammonemia with some malignancies such as multiple myeloma, plasma cell leukemia, and leiomyosarcoma, or in some patients who have received chemotherapy. This case may suggest an association between hyperammonemia and neuroendocrine tumors.Yayın Hyperbaric oxygen therapy does not potentiate doxorubicin-induced cardiotoxicity in rats.(Wiley Online Library, 2008) Karagöz, B.; Süleymanoğlu, S.; Uzun, G.; Bilgi, O.; Aydınöz, S.; Haholu, A.; Önem, Y.; Kandemir, E. G.Abstract: The current use of doxorubicin is regarded as an absolute contraindication for hyperbaric oxygen (HBO2) therapy because of the increased risk of cardiotoxicity. The aim of this study was to investigate whether additional exposure to HBO2 during the course of doxorubicin treatment would further increase the cardiotoxicity of doxorubicin in rats. Female Wistar rats were treated with either HBO2 (n = 10) or doxorubicin (n = 8) or a combination of both treatments (n = 10) for 4 consecutive weeks and followed up for an additional 4 weeks. Cardiomyopathy was evaluated using two-dimensional and M-mode echocardiography at baseline, at the fourth, sixth and eighth weeks, and by histopathological investigation of the rat hearts at the eighth week. Doxorubicin treatment significantly reduced ejection fraction and fractional shortening (P < 0.001) and caused severe histopathological injury (P < 0.05) indicating development of cardiotoxicity. Although the combination of doxorubicin and HBO2 also markedly reduced ejection fraction and fractional shortening (P < 0.001), this reduction was significantly less than that of doxorubicin treatment (P < 0.05). HBO2 therapy also attenuated doxorubicin-induced histopathological changes in rat hearts (P < 0.05). HBO2 alone did not alter echocardiographic parameters or histopathological findings (P > 0.05). In conclusion, HBO2 therapy does not potentiate doxorubicin-induced cardiotoxicity in rats. Cardioprotection conferred by HBO2 against doxorubicin warrants further investigation.Yayın Lung cancer with muscle metastasis that is achieved long disease free survival by multimodal therapy: a case.(Türk Medline, 2008) Karagöz, B.; Bilgi, O.; Mahiroğulları, M.; Çermik, A.; Görür, R.; Kandemir, E. G.Küçük hücreli dışı akciğer kanseri en sık plevra, kemik, beyin, perikard ve karaciğere metastaz yapmaktadır. İskelet kası kapladığı kütle ve vasküler bir organ olmasına karşın ender metastaz yeridir. Burada ilk bulgu olarak kas metastazı ile başvuran küçük hücreli dışı akciğer kanserli bir olgu sunulmuştur. 50 yaşında erkek hasta, sağ femoral bölgede ağrı ve şişkinlik yakınmasıyla başvurdu. Radyolojik incelemede kas yapısı içinde kemik destrüksiyonuna yol açmış solid kitle saptandı. Eksizyonel biyopsi ile metastatik adenokarsinom tespit edildi. Primer odak araştırılmasında radyolojik görüntüleme ile sağ akciğer üst lob yerleşimli kitle saptandı. Sağ üst lobektomi uygulandı. Patolojik değerlendirme kas metastazındaki ile benzer bulundu. Adjuvan kemoterapi verildi. Hasta primer cerrahi, metastazektomi ve adjuvan kemoterapiden 36 ay sonra hastalıksız izlenmektedir.Yayın Metastasis to the epididymis and spermatic cord from colon adenocarcinoma: A case report(Türk Medline, 2008) Karagöz, B.; Bilgi, O.; Küçükodacı, Z.; Soydan, H.; Özgün, A.; Yılmaz, B.; Sönmez, G.; Kandemir, E. G.Metastasis to the epididymis and spermatic cord rare. We presented a case of colon adenocarcinoma with epididymis and spermatic cord metastasis. Sixtyeight years old man with kolon carcinoma has been treated for 3 years. A painless scrotal mass and hydrocel has been detected. A orchiectomy has performed. Histopathologic examination showed metastasis to epididymis, rete testis, ductus deference, and paratesticular soft tissue from colonic adenocarcinoma. The patient has been followed for six months after diagnosis of paratesticular metastasis. The suspected route of dissemination to paratesticular tissues is transperitoneal seeding and hematogenous dissemination, because existence of abdominal and pelvic metastasis. Metastases to atypical sites as paratesticular tissues occur in patients with advanced cancer, although anatomic localization is inadequate.Yayın Oral etoposide-induced leucocytoclastic vasculitis in a patient with lung carcinoma(Wiley Online Library, 2007) Karagöz, B.; Bilgi, O.; Doğan, B.; Kandemir, E. G.; Kunter, E.Oral etoposide-induced leucocytoclastic vasculitis in a patient with lung carcinomaYayın Pre-treatment haemoglobin concentration is a prognostic factor in patients with early-stage breast cancer(Sage Journals, 2005) Kandemir, E. G.; Mayadağlı, A.; Yaylacı, M.; Öztürk, A.We investigated the prevalence of anaemia (haemoglobin concentration < 12 g/dl) in 336 women with early-stage breast cancer and its association with other known prognostic factors. The median follow-up period was 60.5 months (range 9-123 months). Seventy-nine women (23.5%) had a low pre-treatment haemoglobin concentration, but anaemia was not correlated with age, tumour size, nodal status, histological grade or hormone receptor status. Univariate analysis revealed that disease-free survival and overall survival were shorter in patients with anaemia at the time of diagnosis than in patients with normal haemoglobin concentrations. Anaemia remained a significant prognostic factor for disease-free survival and overall survival in the multivariate analysis (relative risk, 1.884 and 1.785, respectively). These results suggest that pre-treatment haemoglobin concentration is an independent prognostic factor in patients with early-stage breast cancer.Yayın Prevalance and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC)(AEPress, 2003) Kunter, E.; Çermik, H.; Işıtmangil, T.; Kandemir, E. G.; Yaylacı, Mustafa; Öztürk, A.The c-erbB2 oncoprotein is highly expressed in approximately one third of non-small cell lung cancer (NSCLC) patients. We determined the status of c-erbB2 expression in our patients with NSCLC and investigated its correlation with disease stage, histological type and response to treatment. Eighty-four patients were examined for the expression of c-erbB2 by immunohistochemistry using a polyclonal antibody. The scoring criteria of Clinical Trial Assay (CTA) were used to evaluate staining (0 to +3). c-erbB2 overexpression was determined in 35% of the cases. Tumors from higher stage disease (stage IIIb-IV) were more often c-erbB2 positive in adenocarcinoma (ADC) (p=0.04). In addition, there was an association between c-erbB2 score and disease stage in ADC patients (p=0.03). Our study did not demonstrate an association of c-erbB2 overexpression with response to chemotherapy. We conclude that c-erbB2 overexpression may be a prognostic marker for evaluating tumor progression in NSCLC patients but further studies must be performed with larger patient populations.Yayın Prognostic significance of thrombocytosis in node-negative colon cancer(Sage Journals, 2005) Kandemir, E. G.; Mayadağlı, A.; Karagöz, B.; Bilgi, O.; Yaylacı, M.Several clinical studies have shown that thrombocytosis is a poor prognostic factor in some types of cancer, but data about the impact of thrombocytosis on prognosis in patients with colon cancer are very limited. We investigated the prevalence and prognostic effect of pre-operative thrombocytosis, defined as a platelet count > 400 × 109/l, retrospectively in patients with node-negative colon cancer. Out of 198 patients, 24 (12.1%) had thrombocytosis, and its presence correlated with tumour depth and lymphatic invasion. Univariate analysis revealed that disease-free survival and overall survival were shorter in patients with pre-operative thrombocytosis than those without thrombocytosis. On multivariate analysis, thrombocytosis alone retained significance as a poor prognostic factor for both disease-free survival and overall survival. In conclusion, this study shows an association between thrombocytosis and poor survival in patients with node-negative colon cancer. The pre-operative platelet count may help to identify patients with an unfavourable prognosis in this subgroup.
